| ［1］ Sohal DP, Metz JM, Sun WJ, et al. Cancer chemother pharmacol［J］. Cancer Chemother Pharmacol, 2013, 71: 14851491.
［2］ Nakai Y, Isayama H, Sasaki T, et al. Impact of S1 on the survival of patients with advanced pancreatic cancer［J］. Pancreas, 2010, 39(7): 989993. DOI: 10.1097/MPA.0b013e3181d91936.
［3］ Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5fluorouracil (OFF) plus BSC in patients for secondline advanced pancreatic cancer: a phase Ⅲstudy from the German CONKOstudy group［J］. Eur J Cancer, 2011, 47(11): 16761681. DOI: 10.1016/j.ejca.2011.04.011.
［4］ Tempero M, Arnoletti JP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2. 2012: featured updates to the NCCN guidelines［J］. J Natl Compr Cancer Netw, 2012, 10(6): 703713.
［5］ Ueno H, Ioka T, Ikeda M, et al. Randomized phase Ⅲ study of gemcitabine plus S1, S1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study［J］. J Clin Oncol, 2013, 31(13): 16401648. DOI: 10.1200/JCO.2012.43.3680.
［6］ Schultheis B, Strumberg D, Bergmann L, et al. Results of a phase Ⅱ trial of S1 as firstline treatment of metastatic pancreatic cancer (CESARstudy group)［J］. Invest New Drugs, 2012, 30(3): 11841192. DOI: 10.1007/s106370119665x.
［7］ Ghosn M, Saroufim A, Kattan J, et al. Sequential FOLFOX6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer［J］. Med Oncol, 2012, 29(4): 28312837. DOI: 10.1007/s1203201201979.
［8］ Takahara N, Isayama H, Nakai Y, et al. A retrospective study of S1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer［J］. Cancer Chemother Pharmacol, 2013, 72(5): 985990. DOI: 10.1007/s0028001322787. |
